Switch treatment after poor initial chemo response for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether switching to a different chemotherapy or going straight to radiation helps patients whose nasopharyngeal cancer did not shrink after two rounds of initial chemotherapy. It compares two approaches to see which is more effective for people whose cancer is stable or growing after induction chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a specific type of nasopharyngeal cancer (non-keratinizing, WHO Type II or III).
- Your cancer is locally advanced (stage II or III, meaning it has spread to nearby lymph nodes or tissues but not to distant organs).
- You have completed two cycles of standard induction chemotherapy and the tumor did not shrink (it stayed the same or grew).
- You are in good physical condition (able to do daily activities) and your bone marrow, liver, and kidneys work well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
This trial tests whether adding chemotherapy to a combination of immunotherapy and radiation is more effective than immunotherapy and radiation alone for advanced nasopharyngeal cancer. It is for people whose cancer has not spread to distant organs.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.